Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
5.87
-0.24 (-3.93%)
Mar 31, 2025, 3:40 PM EDT - Market open
Journey Medical Revenue
In the year 2024, Journey Medical had annual revenue of $56.13M, down -29.11%. Journey Medical had revenue of $13.62M in the quarter ending December 31, 2024, a decrease of -10.73%.
Revenue (ttm)
$56.13M
Revenue Growth
-29.11%
P/S Ratio
2.22
Revenue / Employee
$1,369,122
Employees
41
Market Cap
135.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
DERM News
- 4 days ago - Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 7 days ago - Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea - GlobeNewsWire
- 11 days ago - Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 - GlobeNewsWire
- 19 days ago - Journey Medical Corporation to Participate in the 37th Annual ROTH Conference - GlobeNewsWire
- 25 days ago - Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea - GlobeNewsWire
- 26 days ago - Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida - GlobeNewsWire
- 7 weeks ago - Stock Picks From Seeking Alpha's January 2025 New Analysts - Seeking Alpha